Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework

Mara ten Kate*, Frederik Barkhof, Marina Boccardi, Pieter Jelle Visser, Clifford R. Jack, Karl-Olof Lovblad, Giovanni B. Frisoni, Philip Scheltens, Geneva Task Force Roadmap Alzhei

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)167-182
Number of pages16
JournalNeurobiology of Aging
Volume52
DOIs
Publication statusPublished - Apr 2017

Keywords

  • Alzheimer's disease
  • Dementia
  • Mild cognitive impairment
  • Hippocampus
  • Medial temporal lobe atrophy
  • MRI
  • Roadmap
  • MILD COGNITIVE IMPAIRMENT
  • ADNI HARMONIZED PROTOCOL
  • REGISTERED SERIAL MRI
  • VASCULAR RISK-FACTORS
  • VISUAL RATING-SCALES
  • LOBE ATROPHY
  • HIPPOCAMPAL VOLUME
  • MAGNETIC-RESONANCE
  • APOLIPOPROTEIN-E
  • FRONTOTEMPORAL DEMENTIA

Cite this

ten Kate, M., Barkhof, F., Boccardi, M., Visser, P. J., Jack, C. R., Lovblad, K-O., Frisoni, G. B., Scheltens, P., & Geneva Task Force Roadmap Alzhei (2017). Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. Neurobiology of Aging, 52, 167-182. https://doi.org/10.1016/j.neurobiolaging.2016.05.024